尿激酶与瑞替普酶在急性心肌梗死溶栓治疗中的疗效对比

Comparison of the Efficacy of Urokinase and Reteplase in Thrombolytic Therapy of Acute Myocardial Infarction

目的:研究对比尿激酶与瑞替普酶在急性心肌梗死溶栓治疗中的应用效果。方法:选取某院在2016年1月~2018年12月收治的102例急性心肌梗死患者,采用随机数字表法分为参照组和实验组各51例,对参照组施以尿激酶溶栓治疗,对实验组施以瑞替普酶溶栓治疗,对比两组患者的血管再通率以及心脏不良事件发生率。结果:实验组患者的血管再通率为86.27%,高于参照组的62.75%;实验组患者的心脏不良事件发生率为3.92%,低于参照组的19.61%(P<0.05)。两组患者的不良反应发生率比较无差异(P>0.05)。结论:在急性心肌梗死治疗中,采用瑞替普酶溶栓疗法,血管再通效果好,且可降低心脏不良事件的发生风险,相比尿激酶更具临床应用及推广价值。

Objective:To compare the effects of urokinase and reteplase in thrombolytic therapy of acute myocardial infarction.Methods:102 patients with acute myocardial infarction admitted to a hospital from January 2016 to December 2018 were selected and randomly divided into two groups.The reference group(n=51)was treated with urokinase thrombolytic therapy,and the experimental group(n=51)was treated with reteplase thrombolytic therapy,then the revascularization rate and the incidence of adverse cardiac events were compared between the two groups.Results:The recanalization rate of the experimental group was 86.27%,which was higher than that of the reference group(62.75%).The incidence of adverse cardiac events in the experimental group was 3.92%,which was lower than that in the reference group(19.61%)(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The application of reteplase thrombolytic therapy in the treatment of acute myocardial infarction has good effect on revascularization,and can reduce the risk of adverse cardiac events,which has more clinical application and promotion value than urokinase.